Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

4 Results

Guidelines and Advice

Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib (Iressa®), Erlotinib (Tarceva®), Afatinib, Dacomitinib or Icotinib in the Treatment of Non–SmallCell Lung Cancer: A Clinical Practice Guideline

Status: In-Review
ID: 7-9
Version: 2

Apr 2014

Guidelines and Advice

Position Statements for Nursing Practice in Cancer Care

Status: Current
Version: 2

May 2021

Guidelines and Advice

Position Statements for the Implementation of Oncology Biosimilars from the pan-Canadian Clinical Operations Working Group

Status: Current
Version: 1

Aug 2019

Guidelines and Advice

Person-Centred Virtual Cancer Care Clinical Guidance

Status: Current
Version: 2

Jan 2022